Phase 2 of coronavirus vaccine human trials may begin in spring – CNBC

Ross J Burland FXStreet

CNBC reports that a phase 2 of coronavirus vaccine human trials may begin in spring, Moderna chairman says, resultant to out a specific date on things as it is a very dynamic situation.

CNBC's Key points

The first human trial of a vaccine to prevent the new coronavirus could advance to the next step this spring, Moderna Chairman Noubar Afeyan said Thursday.
“We’ll enter hopefully phase 2 trials, we expect that to happen in the spring, perhaps early summer,” Afeyan told CNBC’s Meg Tirrell.
“It’s difficult to put a specific date on things just because it’s a very dynamic situation,” he added.

EUR/USD price analysis

The EUR/USD pair is pressuring the 61.8% retracement of its latest bullish run, maintaining its negative bias ahead of the Asian opening. In the 4-hour chart, the pair is extending its slide below all of its moving averages, with the 20 SMA moving below the larger ones, although all of them still confined to a tight range. Technical indicators in the mentioned chart stand at daily lows although losing their bearish strength. Anyway, the risk remains skewed to the downside, with the market looking to re-test the yearly low at 1.0635

– Valeria Bednarik, Chief Analyst at FXStreet explained.

EUR/USD Forecast: Dollar demand overshadows discouraging data

Author

Ross J Burland

FXStreet

Ross J Burland, born in England, UK, is a sportsman at heart. He played Rugby and Judo for his county, Kent and the South East of England Rugby team.

EUR/USD remains on the back foot near 1.1750

EUR/USD is coming under renewed pressure, sliding towards multi-week lows in the mid-1.1700s on Thursday. The move lower reflects another strong session for the US Dollar, with the Greenback drawing fresh support from a batch of firm US data that reinforced its underlying bid.

GBP/USD drops further, hovers around 1.3460

GBP/USD is sliding in tandem with its risk-sensitive peers, drifting back towards the 1.3440 area, its lowest levels in around four weeks. The move reflects a firmer Greenback, supported by another round of solid US data, while a somewhat divided FOMC Minutes has added an extra layer of uncertainty around the Fed’s rate path, keeping Cable on the defensive.

Gold struggles to overcome $5,000

Gold is trading with humble gains on Thursday, hovering around the key $5,000 mark per troy ounce. The yellow metal remains underpinned by renewed geopolitical tensions in the Middle East, even as a stronger US Dollar and rising US Treasury yields across the curve limit the upside and keep price action relatively contained.

Ripple slips toward $1.40 despite SG-FORGE tapping protocol for EUR CoinVertible

XRP extends its decline, nearing $1.40 support, as risk appetite fades in the broader market. SG-FORGE’s EUR CoinVertible launches on the XRP Ledger, leveraging the blockchain’s scalability, speed, security, and decentralization.

Hawkish Fed minutes and a market finding its footing

It was green across the board for US Stock market indexes at the close on Wednesday, with most S&P 500 names ending higher, adding 38 points (0.6%) to 6,881 overall. At the GICS sector level, energy led gains, followed by technology and consumer discretionary, while utilities and real estate posted the largest losses.

Injective token surges over 13% following the approval of the mainnet upgrade proposal

Injective price rallies over 13% on Thursday after the network confirmed the approval of its IIP-619 proposal. The green light for the mainnet upgrade has boosted traders’ sentiment, as the upgrade aims to scale Injective’s real-time Ethereum Virtual Machine architecture and enhance its capabilities to support next-generation payments.